Research and Markets (http://www.researchandmarkets.com/research/h4grg5/endocrine_testing) has announced the addition of the "Global Flonal Endocrine Testing Market Opportunities 2013-2019 - Analysis of the $1.53 Billion Industry" report to their offering.
The global market for endocrine testing market was valued at USD 1,537.5 million in 2012 growing at a CAGR of 4.3% from 2013 to 2019.
Endocrine tests are crucial for monitoring normal functioning of endocrine system since any deviation (hypersecretion or hyposecretion) from the normal levels of hormones results in development of various endocrine disorders such as diabetes, thyroid, cancer and infertility. These tests enable both qualitative and quantitative determination of the hormone levels and can be performed either in hospitals, commercial laboratories (thyroid hormone tests, progesterone tests) or even at home (pregnancy test kit, blood sugar test strips). Endocrine testing market is witnessing increasing growth and adoption majorly due to constant rise in several disorders such as diabetes, thyroid and reproductive system disorders. These disorders indicate the abnormal level of endocrine hormones in the body thereby creating a need and demand for effective endocrine testing kits. In addition, continuous evolution of diagnostic platforms followed by increasing healthcare awareness would further augment the growth and development of endocrine testing platforms.
Endocrine testing market can be analyzed by the type of tests involved, diagnostic platforms and end users. The various hormone tests refer to estradiol, Follicle Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), Luteinizing Hormone (LH), Dehydroepiandrosterone sulfate (DHEAS), Progesterone, Testosterone, Thyroid Stimulating Hormone (TSH), Prolactin, Cortisol, Insulin tests and others. Thyroid stimulating hormone test market was estimated to be the largest market segment in 2012 growing at a CAGR of 5.4% during the forecast period. This is attributed to high prevalence of thyroid disorders among geriatric population and also is more common in females than males with a female to male ratio of 10:1. Also, as per the research findings published in Elsevier, Inc., among the population aged above 65, 1.7% have hypothyroidism and 13.7% of aging population have subclinical hypothyroidism. Insulin test is expected to be the fastest growing segment during the forecast period from 2013 to 2019. The major reason being constant rise in diabetic and obese population across the globe.
The global endocrine testing market is segmented into the following categories:
- Estradiol (E2) Test
- Follicle Stimulating Hormone (FSH) Test
- Human Chorionic Gonadotropin (hCG) Test
- Luteinizing Hormone (LH) Test
- Dehydroepiandrosterone sulfate (DHEAS) Test
- Progesterone Test
- Testosterone Test
- Thyroid Stimulating Hormone (TSH) Test
- Prolactin Test
- Cortisol Test
- Insulin Test
- Others (Gastrin, Thymosin, Secretin, etc.)
- Tandem Mass spectrometry
- Immunoassay (Enzyme immunoassays, Radioimmunoassays (RIA)) Technologies
- Monoclonal and Polyclonal Antibody Technologies
- Sensor (Electrochemical, Biosensors, etc.) Technologies
- Clinical Chemistry Technologies
- Others (Liquid Chromatography + Mass Spectrometry (LC-MS), High performance Liquid Chromatography (HPLC), etc.)
- Commercial Laboratories
- Ambulatory Care Centers
- Home Based Tests
- Physician Offices
- Abbott Laboratories
- AB SCIEX LLC
- Agilent Technologies
- Biomedical Diagnostics
- Bio-Rad Laboratories, Inc.
- DiaSorin S.p.A
- F. Hoffmann-La Roche Ltd.
- Laboratory Corporation of America Holdings (LabCorp)
- Ortho Clinical Diagnostics
- Quest Diagnostics
- Siemens Healthcare
- Sysmex Corporation
- Thermo Fisher Scientific
For more information visit http://www.researchandmarkets.com/research/h4grg5/endocrine_testing
- Health Care Industry
- endocrine system
- endocrine disorders